Rothschild Investment Corp IL decreased its position in shares of Eli Lilly and Company (NYSE:LLY) by 0.6% during the second quarter, Holdings Channel reports. The fund owned 26,925 shares of the company’s stock after selling 151 shares during the period. Rothschild Investment Corp IL’s holdings in Eli Lilly and were worth $2,216,000 at the end of the most recent quarter.

A number of other institutional investors have also recently modified their holdings of the stock. First Command Financial Services Inc. raised its position in shares of Eli Lilly and by 7.3% in the first quarter. First Command Financial Services Inc. now owns 1,227 shares of the company’s stock worth $103,000 after buying an additional 84 shares during the last quarter. Heritage Trust Co purchased a new position in shares of Eli Lilly and during the first quarter worth about $135,000. Point72 Asia Hong Kong Ltd raised its position in shares of Eli Lilly and by 237.4% in the first quarter. Point72 Asia Hong Kong Ltd now owns 1,761 shares of the company’s stock worth $148,000 after buying an additional 1,239 shares during the last quarter. Penserra Capital Management LLC raised its position in shares of Eli Lilly and by 9.5% in the first quarter. Penserra Capital Management LLC now owns 2,024 shares of the company’s stock worth $170,000 after buying an additional 176 shares during the last quarter. Finally, American National Bank raised its position in shares of Eli Lilly and by 5.2% in the second quarter. American National Bank now owns 2,088 shares of the company’s stock worth $172,000 after buying an additional 104 shares during the last quarter. 75.61% of the stock is owned by hedge funds and other institutional investors.

Eli Lilly and Company (NYSE LLY) traded down 0.18% during trading on Friday, reaching $81.38. 1,238,683 shares of the company’s stock traded hands. The firm has a market cap of $85.86 billion, a PE ratio of 35.21 and a beta of 0.34. The firm has a 50 day moving average price of $83.00 and a 200-day moving average price of $81.69. Eli Lilly and Company has a 12 month low of $64.18 and a 12 month high of $86.72.

Eli Lilly and (NYSE:LLY) last announced its earnings results on Tuesday, July 25th. The company reported $1.11 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of $1.05 by $0.06. Eli Lilly and had a net margin of 11.12% and a return on equity of 28.71%. The firm had revenue of $5.82 billion for the quarter, compared to analyst estimates of $5.60 billion. During the same quarter in the prior year, the business posted $0.86 EPS. The business’s revenue was up 7.8% compared to the same quarter last year. On average, analysts forecast that Eli Lilly and Company will post $4.16 earnings per share for the current fiscal year.

The firm also recently announced a quarterly dividend, which will be paid on Friday, September 8th. Shareholders of record on Tuesday, August 15th will be given a dividend of $0.52 per share. The ex-dividend date of this dividend is Friday, August 11th. This represents a $2.08 dividend on an annualized basis and a dividend yield of 2.54%. Eli Lilly and’s payout ratio is presently 90.04%.

TRADEMARK VIOLATION WARNING: This piece of content was reported by Daily Political and is the property of of Daily Political. If you are accessing this piece of content on another domain, it was illegally stolen and republished in violation of U.S. & international copyright and trademark laws. The legal version of this piece of content can be accessed at https://www.dailypolitical.com/2017/08/11/rothschild-investment-corp-il-reduces-position-in-eli-lilly-and-company-nyselly.html.

A number of brokerages have issued reports on LLY. BidaskClub raised Eli Lilly and from a “sell” rating to a “hold” rating in a research note on Wednesday, June 14th. Barclays PLC increased their price target on Eli Lilly and from $85.00 to $90.00 and gave the company an “overweight” rating in a research note on Tuesday, July 4th. BMO Capital Markets reaffirmed a “sell” rating and set a $73.00 price target on shares of Eli Lilly and in a research note on Friday, August 4th. Berenberg Bank reaffirmed a “buy” rating and set a $100.00 price target on shares of Eli Lilly and in a research note on Thursday, July 27th. Finally, Jefferies Group LLC reaffirmed a “buy” rating and set a $96.00 price target (up from $93.00) on shares of Eli Lilly and in a research note on Thursday, July 13th. Two investment analysts have rated the stock with a sell rating, eight have assigned a hold rating and twelve have given a buy rating to the company. Eli Lilly and has a consensus rating of “Hold” and an average price target of $88.27.

In other Eli Lilly and news, insider Melissa S. Barnes sold 1,900 shares of the stock in a transaction that occurred on Monday, June 12th. The shares were sold at an average price of $80.78, for a total transaction of $153,482.00. Following the transaction, the insider now owns 14,041 shares in the company, valued at approximately $1,134,231.98. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, VP Michael J. Harrington sold 22,833 shares of the stock in a transaction that occurred on Friday, June 9th. The stock was sold at an average price of $79.97, for a total transaction of $1,825,955.01. Following the transaction, the vice president now owns 62,056 shares in the company, valued at approximately $4,962,618.32. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 669,733 shares of company stock worth $55,845,287. Company insiders own 0.20% of the company’s stock.

Eli Lilly and Company Profile

Eli Lilly and Company is engaged in drug manufacturing business. The Company discovers, develops, manufactures and markets products in two segments: human pharmaceutical products and animal health products. The Company’s human pharmaceutical business segment sells medicines, which are discovered or developed by its scientists.

Want to see what other hedge funds are holding LLY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Eli Lilly and Company (NYSE:LLY).

Institutional Ownership by Quarter for Eli Lilly and (NYSE:LLY)

Receive News & Ratings for Eli Lilly and Company Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eli Lilly and Company and related companies with MarketBeat.com's FREE daily email newsletter.